NCT03525444: A reported trial by Vertex Pharmaceuticals Incorporated
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03525444 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 15, 2018 |
| Completion date | April 24, 2019 |
| Required reporting date | April 23, 2020, midnight |
| Actual reporting date | April 22, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 23, 2025 |
| Days late | None |